Abstract
Schiff bases of isatin 1-20 were synthesized and tested for their antiglycation potential. Compound 6 showed 77% inhibition with an IC50= 177.2 ± 0.4 μM, which is an excellent antiglycation activity, if compared with standard aminoguanidine having 85.69% inhibition with an IC50 value 268.7 ± 12.4 μM. Compound 3 showed 71.3% inhibition with an IC = 675 ± 0.12 μ/M, which is moderately active antiglycation agent. Although compounds 1, 2, 5, 7-15, and 17- 19 demonstrated over 50% inhibition in preliminary screening, but found inactive when further evaluated for their IC values. However, compounds 4, 16, 20, and parent isatin showed less than 50% inhibition and considered to be completely inactive. The structures of all the synthesized compounds were determined by spectroscopic analysis, including UV, IR, mass and 1H-NMR spectrometry. All compounds gave satisfactory elemental analysis.
Keywords: Synthesis, Isatin, Schiff bases, Antiglycation, Lead molecules
Letters in Drug Design & Discovery
Title: Schiff Bases of Istain: Antiglycation Activity
Volume: 6 Issue: 5
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Nida Ambreen, Ambreen Khan, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Synthesis, Isatin, Schiff bases, Antiglycation, Lead molecules
Abstract: Schiff bases of isatin 1-20 were synthesized and tested for their antiglycation potential. Compound 6 showed 77% inhibition with an IC50= 177.2 ± 0.4 μM, which is an excellent antiglycation activity, if compared with standard aminoguanidine having 85.69% inhibition with an IC50 value 268.7 ± 12.4 μM. Compound 3 showed 71.3% inhibition with an IC = 675 ± 0.12 μ/M, which is moderately active antiglycation agent. Although compounds 1, 2, 5, 7-15, and 17- 19 demonstrated over 50% inhibition in preliminary screening, but found inactive when further evaluated for their IC values. However, compounds 4, 16, 20, and parent isatin showed less than 50% inhibition and considered to be completely inactive. The structures of all the synthesized compounds were determined by spectroscopic analysis, including UV, IR, mass and 1H-NMR spectrometry. All compounds gave satisfactory elemental analysis.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Ambreen Nida, Khan Ambreen, Perveen Shahnaz and Choudhary Iqbal Muhammad, Schiff Bases of Istain: Antiglycation Activity, Letters in Drug Design & Discovery 2009; 6(5) . https://dx.doi.org/10.2174/1570180810906050358
DOI https://dx.doi.org/10.2174/1570180810906050358 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Editorial [Hot Topic: Potential New Therapeutic Strategies of Diabetic Vascular Complications (Guest Editor: Toyoshi Inoguchi)]
Current Drug Targets Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy The Healing Effects of Spices in Chronic Diseases
Current Medicinal Chemistry Assessment of Glomerular and Tubular Function
Current Pediatric Reviews Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Acute Effects of Neutrophil-Derived Oxidative Stress on Pulmonary Microvasculature
Current Respiratory Medicine Reviews C-peptide and Neuropathy in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry